Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis
Background: Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI) and unstable angina (UA). One treatme...
Main Authors: | Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale, Nigel Fleeman, Joanne McEntee, Yenal Dundar, Marty Richardson, Michael Fisher |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2015-04-01
|
Series: | Health Technology Assessment |
Online Access: | https://doi.org/10.3310/hta19290 |
Similar Items
-
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
by: J Greenhalgh, et al.
Published: (2010-05-01) -
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
by: Nigel Fleeman, et al.
Published: (2020-01-01) -
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
by: Nigel Fleeman, et al.
Published: (2019-12-01) -
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
by: Janette Greenhalgh, et al.
Published: (2015-06-01) -
The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
by: Amanda Nicholson, et al.
Published: (2015-10-01)